Support: 888-992-3836
Copyright © 2023 InvestorsHub Inc.
Replies to post #25012 on NorthWest Biotherapeutics Inc (NWBO)
austinmediainc
11/26/14 12:00 PM
#25014 RE: lunatick #25012
I thought for HE and reimbursement in Germany the Frauenhofer Institut is manufacturing. Or I am wrong?
BETHESDA, MD, July 25, 2012 — Northwest Biotherapeutics, Inc. (OTC.BB: NWBO) (the “Company” or “Northwest Bio”) announced today that its partner in Germany, Fraunhofer IZI, has received the official approval and certification from the regional and national regulatory agencies in Germany (including the Paul-Ehrlich-Institut, or PEI – the German equivalent of the U.S. FDA) for the manufacture of Northwest Bio’s DCVax®-L immune therapy for human patients with Glioblastoma multiforme brain cancer. Fraunhofer IZI will be able to manufacture DCVax®-L in Germany and supply the DCVax®-L product for clinical trials both in Germany and throughout the European Union.
March 10th, 2014 DCVax-L products that are to be covered by the Hospital Exemption in Germany must be manufactured in Germany, but can be administered to patients from anywhere.